Motif Bio Share Discussion Threads

[furryguy] 28/5/2021 11:09

From Hemo on LSE:

"I have set up an email address at [e-mail]

Please let me know if you are ready to vote against the transaction as proposed and how many shares you hold.

I will not respond until next Tuesday when I will report back to everyone on how much interest there is. Depending on that interest we can then approach the Board.

Of course, if someone else wants to take up the crusade I am happy with that and will gladly join. But we must do something and quickly."

[chuffer2] 28/5/2021 09:43

Corporate fraud at it's very best.
The bod are just vile filth

[scottdavid70] 28/5/2021 09:16

I see Iain Ross used to work for Sandoz maybe he can explain the mystery why the former Board members never wanted to explain the two new patents taken out in 2019 on Iclaprim are for? Why have we been told absolutely nothing about Iclaprim for nearly 2 years?

Why have we had no upside for the $18 million in deferred tex in our cash shell value?

These are both potential near term so movers and we have heard zero from our Board about both

[scottdavid70] 28/5/2021 09:14

I see Iain Ross used to work for Sandoz maybe he can explain the mystery why the former Board members never wanted to explain the two new patents taken out in 2019 on Iclaprim are for? Why have we been told absolutely nothing about Iclaprim for nearly 2 years?

Why have we had no upside for the $18 million in deferred tex in our cash shell value?

These are both potential near term so movers and we have heard zero from our Board about both

[tnt99] 27/5/2021 20:04

Does seem a bit of a farce should have researched that the directors had no skin in the game then maybe we would have got a better deal

[scottdavid70] 27/5/2021 17:41

Strange to think you will be able to buy in the open market for cheaper than exercising your warrant as a long term suffering shareholder but the newest shareholders with warrants can have them for 20p or less. Seems so fair that the only people who have lost out are the ones being penalised on the warrant price they can exercise at....

[scottdavid70] 27/5/2021 17:35

Anyone see the Technical Expert’s report that was promised in the 27th January RNS yesterday?


The AIM Admission Document will include a Technical Expert's report which is being prepared in respect of the Target's technology and assets.

The stuff in there yesterday seemed like stuff you can get off the internet very unspecified if anything. Certainly i and others couldn’t find a specific looking report- anyone else?

[small crow] 27/5/2021 17:20

"..then this will be trashed constantly on message boards globally for the greed that has consumed Motif Bio by the Director’s." Who would do a thing like that??

[scottdavid70] 27/5/2021 16:58

Bet BiVictriX Therapeutics Limited are delighted with all the publicity their RTO is getting....such a positive start for them as public company.....NOT - class action shareholders revolts being planned etc

The science is strong but if Motif don’t have a trick up their sleeve with Iclaprim or BiVictriX Therapeutics Limited don’t have a major announcement then this will be trashed constantly on message boards globally for the greed that has consumed Motif Bio by the Director’s.

The market is very hot for these type of innovative cancer cures again but unless there is a substantial piece of news this will be a disaster waiting to happen.

Feel sorry for Tiffany Daniels-Thorn - seems like a tremendous woman who is very driven and has done extremely well. Shame her name will be included with the other types of CEO’s like Graham Lumsden and Jonathan Gold in my book and newspaper stories. Not great for her company to be tainted by that shameless greed on her journey to make patients lives better with AML.

[furryguy] 27/5/2021 14:54

From 'Hemo' on the other board:

"I have set up an email address at [e-mail]

Please let me know if you are ready to vote against the transaction as proposed and how many shares you hold.

I will not respond until next Tuesday when I will report back to everyone on how much interest there is. Depending on that interest we can then approach the Board.

Of course, if someone else wants to take up the crusade I am happy with that and will gladly join. But we must do something and quickly."

[tnt99] 27/5/2021 14:39

I only invested for intclam as world needs more antibiotics but it seems they have parked this outside the deal and don't know our position on any future sale????

[small crow] 27/5/2021 13:39

chuffer, I'm genuinely interested in why you chose to invest in the first place? I'm sure you realised there were risks?

[small crow] 27/5/2021 11:50

"..and Scott goes quiet." Thankfully.

[40 fathoms] 27/5/2021 08:16

With the 9 mln I think the intention would be to partner and not to take it all the way through trials on their own. This area is super hot Merck just paid US$ 2.75bn for VelosBio, and Sanofi Euro 1.5 billion for Kymab.

[jibba jabber] 27/5/2021 07:16

Also, it costs way way way more than 9mln to get a product through trials to market, where will that money come from other than further placings and dilution, this is a scandal of epic proportions, never seen anything quite as bad as this in 20 odd years

[morrie1234] 27/5/2021 07:10

As part of the reverse acquisition and fundraise proposals, the enlarged group will receive net proceeds of approximately £9 million (after deducting expenses) which are expected to be used to accelerate the lead optimisation of BVX001 to reach key preclinical milestones on efficacy and safety, as well as to expand BiVictriX's early-stage pipeline to include two additional candidates with preclinical proof of concept. In addition, the aim is to grow BiVictriX's intellectual property portfolio to add further protection around the lead programme potential avenues for platform intellectual property generation and defensibility of BiVictriX's approach. The directors of the enlarged group believe the Bi-Cygni® approach can be applied to build a diverse pipeline of first-in-class therapeutics across the wider spectrum of immunotherapeutic platforms, addressing key unmet medical needs in the market. BiVictriX's ambition is to validate the B-Cygni® approach within a panel of difficult-to-treat cancer indications to demonstrate to the market the wide applicability of the concept, building the enlarged group into a global leader in this field.